Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation
Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation
08/28/24, 11:05 AM
Location
morrisvilleMoney
$2 million
Industry
biotechnology
Type
agreement
Lindy Biosciences has announced a multi-target exclusive global licensing agreement and strategic collaboration with Novartis Pharma AG, focusing on transitioning select innovative medicines to self-administered subcutaneous injections using Lindy Biosciences’ proprietary technology. The collaboration aims to increase the maximum dose that can be administered in a single subcutaneous injection, potentially reducing healthcare costs and improving patient comfort and treatment compliance.
Company Info
Location
627 davis drive
morrisville, north carolina, united states
Additional Info
Lindy Biosciences is a development-stage protein therapeutic formulations company. Our core technology, Microglassification™, produces spherical, dense, stable particles of a therapeutic protein. These protein particles are ideal for long-term storage, or for incorporation into drug delivery formulations such as suspensions(for high-concentration delivery of antibodies), encapsulation (for sustained/controlled release), or dry powder pulmonary delivery.
Related People
Unlock Verified Contacts + AI Outreach
Instantly access verified contact emails — and let Fundz AI draft a hyper-personalized message based on their role, company, and your company's offering.
h
h • Executive
Email hidden • Upgrade to unlock
Trusted by teams at Google, Oracle, HubSpot & more
Unlock Verified Contacts + AI Outreach
Instantly access verified contact emails — and let Fundz AI draft a hyper-personalized message based on their role, company, and your company's offering.
Dh
Dh • Executive
Email hidden • Upgrade to unlock
Trusted by teams at Google, Oracle, HubSpot & more